Pretax income is the income that a company earns before paying income taxes. Iterum Therapeutics's pretax income for the
three
months ended in Mar. 2024 was $-7.05 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-35.05 Mil.
Iterum Therapeutics's pretax margin was %.
During the past 8 years, Iterum Therapeutics's highest Pretax Margin was -5701.18%. The lowest was -277529.73%. And the median was -8812.89%.
Iterum Therapeutics Pre-Tax Income Historical Data
The historical data trend for Iterum Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Iterum Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Iterum Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's Pre-Tax Income falls into.
Iterum Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Iterum Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (NAS:ITRM) Pre-Tax Income Explanation
Iterum Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 8 years, Iterum Therapeutics's highest Pretax Margin was -5701.18%. The lowest was -277529.73%. And the median was -8812.89%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Iterum Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Iterum Therapeutics (Iterum Therapeutics) Business Description
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ITRM has been successfully added to your 